Latest Breaking News On - Genexine inc - Page 4 : comparemela.com

Genexine, Inc : Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced

Soult ukpyolsiSouth koreaUnited statesFrance generalEdward shinKostenloser wertpapierhandelJongsoo leeEuropean society for medical oncology congressGenexine incKorean financial supervisory serviceMerck co incMerck sharp dohmeMinistry of foodNational cancer drug development project of koreaMedical oncology congressOral session

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Soult ukpyolsiSouth koreaUnited statesEdward shinHye ryun kimJongsoo leeNational institute of healthGenexine incKorean financial services commissionProfessor hye ryun kimYonsei severance hospital cancerProfessor hye ryunNeil warmaNational instituteGrowth hormone deficiencyData analysis

Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer

SEOUL, South Korea (BUSINESS WIRE) Jun 7, 2022

Soult ukpyolsiSouth koreaUnited statesJongsoo leeSohn ju hyukGenexine incAmerican society of clinical oncologyKorean financial services commissionAmerican societyClinical oncologyProfessor sohn ju hyukMedical oncologyYonsei severanceNeil warmaNeoimmune techPediatric growth hormone deficiency

Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation - read this article along with other careers information, tips and advice on BioSpace

Soult ukpyolsiSouth koreaHong kongUnited statesSan diegoMerck seronoGenexine incOpexa therapeutics incBiotechnology innovation organizationUniversity of torontoSchulich school of business at york universityNovartis pharmaceuticalsNeil warmaChief executiveGeneral managerOpexa therapeutics

Genexine to Present at H C Wainwright Global Investment Conference

Genexine to Present at H C Wainwright Global Investment Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Soult ukpyolsiSouth koreaJongsoo leeGenexine incNeil warmaGlobal investment conferenceTuesday mayPediatric growth hormone deficiency